Bart Morlion

TL;DR: Some common fundamental central pain mechanisms are introduced and how they may translate into the clinical signs and symptoms across different chronic pain conditions, how to evaluate gain and loss of function using quantitative pain assessment tools, and the implications for optimising prevention and management of pain are discussed.

TL;DR: An open‐label extension study showed that the initial pain relief was maintained without dose escalation or toxicity for 52 weeks, and the mean reduction in pain intensity scores was greater in patients receiving sativex than placebo.

TL;DR: Buprenorphine exhibits a pronounced antihyperalgesic effect that might indicate potential advantages in the treatment of neuropathic pain, and its favorable safety profile and proven efficacy in severe pain and favorable tolerability mean that it can be considered a safe and effective option for treating chronic cancer and noncancer pain.

TL;DR: The beneficial effects of Gln dipeptide-supplemented TPN on nitrogen economy, maintenance of plasma Gln concentration, lymphocyte recovery, cysteinyl-leukotriene generation, and shortened hospital stay in surgical patients are confirmed.

TL;DR: Despite the increasing clinical use of transder-mal buprenorphine, questions have persisted about the possibility of a ceiling effect for analgesia, its combination as discussed by the authors, and its combination.